Citizens Jmp Comments on Teleflex’s Q2 Earnings (NYSE:TFX)

Teleflex Incorporated (NYSE:TFX) – Citizens Jmp issued their Q2 2026 earnings per share (EPS) estimates for Teleflex in a note issued to investors on Wednesday, May 6th. Citizens Jmp analyst D. Turkaly forecasts that the medical technology company will post earnings of $1.40 per share for the quarter. The consensus estimate for Teleflex’s current full-year earnings is $6.80 per share. Citizens Jmp also issued estimates for Teleflex’s Q3 2026 earnings at $1.85 EPS, Q4 2026 earnings at $1.99 EPS and FY2026 earnings at $6.40 EPS.

TFX has been the subject of several other reports. Mizuho set a $140.00 price target on shares of Teleflex in a report on Friday. Truist Financial restated a “hold” rating and set a $143.00 price objective (up from $135.00) on shares of Teleflex in a research report on Monday. Royal Bank Of Canada raised Teleflex from a “sector perform” rating to an “outperform” rating and upped their target price for the stock from $135.00 to $155.00 in a report on Friday. Wall Street Zen downgraded Teleflex from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, Raymond James Financial reissued an “outperform” rating and set a $150.00 price target on shares of Teleflex in a research note on Friday. Three analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $144.00.

Teleflex Price Performance

Shares of NYSE:TFX opened at $129.00 on Wednesday. Teleflex has a one year low of $100.18 and a one year high of $139.67. The company has a debt-to-equity ratio of 0.82, a current ratio of 2.55 and a quick ratio of 2.03. The company has a market cap of $5.71 billion, a price-to-earnings ratio of -5.66, a PEG ratio of 0.95 and a beta of 0.82. The firm has a 50 day simple moving average of $120.22 and a 200 day simple moving average of $116.70.

Teleflex (NYSE:TFX) last posted its quarterly earnings results on Thursday, May 7th. The medical technology company reported $1.39 earnings per share for the quarter, beating analysts’ consensus estimates of $1.21 by $0.18. The company had revenue of $548.30 million for the quarter, compared to the consensus estimate of $536.91 million. Teleflex had a negative net margin of 35.88% and a positive return on equity of 13.29%. The firm’s quarterly revenue was up 32.3% compared to the same quarter last year. During the same period last year, the company posted $1.44 EPS. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS.

Teleflex Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 31st. Stockholders of record on Friday, March 6th were given a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date was Friday, March 6th. Teleflex’s dividend payout ratio (DPR) is -5.96%.

Hedge Funds Weigh In On Teleflex

A number of hedge funds and other institutional investors have recently made changes to their positions in TFX. Hsbc Holdings PLC boosted its position in shares of Teleflex by 4.7% during the 1st quarter. Hsbc Holdings PLC now owns 1,861 shares of the medical technology company’s stock valued at $222,000 after acquiring an additional 84 shares during the last quarter. Banque Cantonale Vaudoise increased its position in Teleflex by 82.5% in the fourth quarter. Banque Cantonale Vaudoise now owns 250 shares of the medical technology company’s stock worth $31,000 after purchasing an additional 113 shares during the last quarter. Hantz Financial Services Inc. increased its position in Teleflex by 40.5% in the fourth quarter. Hantz Financial Services Inc. now owns 392 shares of the medical technology company’s stock worth $48,000 after purchasing an additional 113 shares during the last quarter. UMB Bank n.a. raised its stake in Teleflex by 57.1% during the fourth quarter. UMB Bank n.a. now owns 311 shares of the medical technology company’s stock valued at $38,000 after purchasing an additional 113 shares in the last quarter. Finally, Maryland State Retirement & Pension System raised its stake in Teleflex by 1.5% during the fourth quarter. Maryland State Retirement & Pension System now owns 8,652 shares of the medical technology company’s stock valued at $1,056,000 after purchasing an additional 129 shares in the last quarter. 95.62% of the stock is owned by institutional investors and hedge funds.

Teleflex News Roundup

Here are the key news stories impacting Teleflex this week:

• Positive Sentiment: Needham & Company reiterated a Buy rating and set a $147 price target, while also forecasting strong future earnings growth, including FY2028 EPS of $12.18 and Q1 2028 EPS of $2.90. Teleflex analyst estimate report
• Positive Sentiment: Citizens JMP published bullish multi-year estimates for Teleflex, projecting FY2027 EPS of $10.50 and quarterly EPS progression through 2027, suggesting confidence in the company’s earnings trajectory. Teleflex analyst estimate report
• Neutral Sentiment: Truist Financial reaffirmed its Hold rating but raised its price target to $143 from $135, signaling a somewhat improved valuation view without a full bullish upgrade. Teleflex hold rating reaffirmed at Truist Financial
• Neutral Sentiment: Analyst consensus for Teleflex’s current fiscal year remains around $6.75-$6.80 EPS, which provides a stable backdrop but does not by itself signal a new catalyst. Teleflex analyst estimate report

Teleflex Company Profile

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.